Conference Coverage
Conference Coverage
Apixaban cuts stroke but ups bleeding in subclinical AFib: ARTESIA
The big question is whether the reduction in stroke with anticoagulation outweighs the increase in major bleeding.
Conference Coverage
Impressive bleeding profile with factor XI inhibitor in AFib: AZALEA
“This gives us real hope that we have finally found an anticoagulant that is remarkably safe,” said Dr. Christian Ruff.
Conference Coverage
Apremilast beats placebo in early PsA affecting few joints
Phase 4 trial offers insight into efficacy in patients whose mild cases have gotten less research attention.
Conference Coverage
Survey: 42% of PCPs not familiar with biologics for asthma
“The results of the survey point to the need to improve the communication between primary care physicians and asthma care specialists, including...
Conference Coverage
Blood pressure lowering reduces dementia risk
“This proven, effective intervention should be widely scaled up to reduce the global burden of dementia.”
Conference Coverage
Alpha-gal syndrome: Red meat is ‘just the beginning,’ expert says
“We are seeing increasing diagnoses of AGS in places that are not, perhaps, where we first thought this allergy existed.”
Conference Coverage
Obinutuzumab promotes renal preservation in lupus nephritis
A post hoc analysis of the NOBILITY trial showed improved outcomes for patients taking obinutuzumab (Gazyva), compared with placebo.
Conference Coverage
CPPD nomenclature is sore subject for gout group
G-CAN hopes to standardize terminology and finally oust ‘pseudo’ vernacular.
Conference Coverage
Semaglutide ‘a new pathway’ to CVD risk reduction: SELECT
The SELECT trial was “a turning point in the treatment of obesity and a call to action.”
Latest News
Prurigo nodularis diagnosis delay in skin of color gains added significance
Given the expanding array of therapies, the message of considering prurigo nodularis in Black patients in order to accelerate the time to...
Conference Coverage
Gout: Studies support early use of urate-lowering therapy, warn of peripheral arterial disease
Urate-lowering drugs might be OK early on; gout may boost peripheral arterial disease.